色谱  2016, Vol. 34 Issue (3): 279-288   PDF (1205 KB)    
扩展功能
加入收藏夹
复制引文信息
加入引用管理器
Email Alert
RSS
本文作者相关文章
Lakkireddy PRAKASH
M HIMAJA
Stress degradation study and structure characterization of oxidation degradation product of dexlansoprazole using liquid chromatography-mass spectrometry/time of flight, liquid chromatography-tandem mass spectrometry and nuclear magnetic resonance
Lakkireddy PRAKASH1,2 , M HIMAJA2    
1. Department of Analytical Research and Development, Dr. Reddy's Laboratories Ltd, IPDO, Hyderabad 500072, India;
2. Pharmaceutical Chemistry Division, School of Advanced Sciences, VIT University, Vellore 632014, India
Abstract: The present study deals with the forced degradation behavior of dexlansoprazole under International Conference on Harmonisation (ICH) prescribed stress conditions. The drug was found to be more labile under acid, base, neutral, oxidative hydrolysis and thermal stress, while it was moderately stable under photolytic conditions. The known and unknown degradation products were separated on a C-18 column using a stability-indicating method. Liquid chromatography-mass spectrometry (LC-MS) analysis was performed for all the degradation studies. Isolation and structure characterization of oxidation degradation products were executed using sophisticated tools, viz. preparative high performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry/time of flight (LC-MS/TOF), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and nuclear magnetic resonance (NMR). This study demonstrates an ample methodology of degradation studies and structure elucidation of unknown degradation products of dexlansoprazole, which helps in the development and stability study of active pharmaceutical ingredients and formulated products.
Key words: stress degradation     isolation     spectral characterization     dexlansoprazole     impurities    

Dexlansoprazole (DLP) is the R enantiomer of lansoprazole and chemically known as (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-lH-benzimidazole. Its empirical formula is C16H14F3N3O2S,with a relative molecular mass of 369.36. DLP is a drug comes under the therapeutic class of gastric acid secretion inhibitor and pharmacologic class of proton pump inhibitor (PPI). It is used to heal and maintain healing of erosive esophagitis (EE) and to treat heartburn associated with gastro esophageal reflux disease (GERD),a condition where the acid in the stomach washes back up into the esophagus. It works by decreasing the amount of acid produced by the stomach [1].

The study of degradation behavior of active pharmaceutical ingredients (API) and finished products (FP) is a critical aspect during their development. Like any other chemicals,a drug also has propensity to degrade over a period of time under the influence of the environmental factors,like relative humidity,temperature,oxygen and sunlight and formulation factors such as water pH,milling,grinding,and granulation. Hence,the knowledge of the structures of degradation products (DPs) and their toxicity is essential from the aspect of safety. Considering potential health concerns,almost all regulatory agencies including World Health Organization (WHO),United States Food and Drug Administration (US FDA) and ICH have included requirements of reporting,identification,characterization and qualification of DPs in their guidelines [2, 3, 4, 5]. Moreover,structural knowledge of DPs and mechanisms of their formation are helpful in developing stable formulations and also to assess the quality of the marketed formulations. Nowadays,hyphenated analytical techniques are widely used for the detection,isolation and structure characterization of impurities and DPs [6, 7, 8, 9].

Although,DLP was approved as Dexilant by US FDA in 2010 [10],not much information exists in literature on identification and characterization of its degradation products. Only,a few analytical methods for the determination of DLP in biological samples [11] and a chiral LC method for enantiomeric separation of DLP [12] have been reported. Few papers reported the synthesis,isolation,identification and characterization of some of the impurities in lansoprazole [13, 14, 15, 16, 17, 18] and development and validation of stability indicating methods for the estimation of lansoprazole and its impurities [19, 20, 21, 22]. But so far there was no literature on degradation study,identification and characterization of degradation products of DLP. Hence,the purpose of the present study is to investigate the stress degradation behavior of the drug and characterization of degradation products (all the impurities of DLP are listed in Table 1),which was carried out by employing the following steps: (i) the drug was subjected to ICH prescribed acid,base,neutral hydrolysis,oxidative,photolytic and thermal stress [23, 24],(ii) the stressed samples were analyzed by HPLC in stability indicating method,(iii) the mass study of the stressed samples was established using LC-MS,(iv) the degradation products were characterized through LC-MS/TOF,LC-MS/MS and NMR.

Table 1 Names, relative retention times (RRTs), relative molecular masses (Mr) and structures of related impurities of DLP
1 Experimental
1.1 Chemicals and reagents

DLP drug used for investigation was obtained from the Research & Development Department of Dr. Reddy’s Laboratories Ltd.,Hyderabad,India. HPLC grade acetonitrile,triethyl amine,ortho phosphoric acid,hydro chloric acid,sodium hydroxide,hydrogen peroxide,ammonium acetate,ammonia and potassium dihydrogen phosphate were obtained from Merck Co.,Mumbai,India. Ultra-pure water was collected from TKA Millipore water purification system. Dimethyl sulfoxide (DMSO)-d6 (for NMR) was obtained from Aldrich Chemical Co.,USA.

1.2 Apparatus and equipment

The chromatography analysis was performed using a Waters Alliance 2695 separation module (Waters Corporation,Milford,USA) equipped with a 2998 Photo Diode Array (PDA) Detector,a degasser,a quaternary pump,and an auto sampler system. The output signal was monitored and processed using Empower 2 software. Preparative isolation work performed on an Agilent 1200 series preparative HPLC system which was equipped with an automated fraction collector and a photodiode array detector. The data was collected and processed using Chemstation software. Rotavapour model: Heidolph Laboratory 4002 was used for solvent evaporation. Lyophilizer (model: Virtis Advantage plus) was used to solidify the impurities. The electro spray ionization and MS/MS studies were performed on triple quadrupole mass spectrometer AB SCIEX model: 4000 QTRAP. The UPLC-MS/TOF system consisted of an ACQUITYTM Ultra Performance Liquid Chromatography (UPLC) system operating in either positive or negative ion mode with electrospray ionisation (ESI) source. NMR experiments (1D and 2D) were performed using a 500 MHz Unity INOVA NMR spectrometer (Varian). Cintex digital water bath was used for hydrolysis studies. Photo stability studies were carried out in photo stability chamber (Sanyo,Leicestershire,UK). Thermal stability studies were performed in a dry air oven (Cintex,Mumbai,India). A pH meter (Thermo Scientific) was used to check and adjust the pH of buffer solutions.

1.3 Forced degradation studies

Forced degradation studies were performed on the DLP drug with the intention to study the stability of DLP under different conditions and to explore the degradation products. Various trials were taken to optimize the degradation conditions. For acid,base hydrolysis and oxidative study 100 mg of DLP was dissolved in 10 mL of diluent (0.1 mol/L NaOH-acetonitrile,75:25 (v/v)),then 10 mL of stressor (0.1 mol/L HCl,0.1 mol/L NaOH,10% (v/v) H2O2) was added to it and refluxed at 40-60 ℃,then neutralized and made up to 100 mL with diluent. For thermal stress study,the drug was kept at 105 ℃ for 24 hours. Photolytic studies were carried out by exposing DLP and its solutions in a photo stability chamber at 1.2 million lux hours and UV light at 200 Watt hours/meter2. Parallel blanks were kept under all the stress conditions. The optimized stress conditions employed are enlisted in Table 2.

Table 2 Optimized stress conditions of DLP degradation study
1.4 Chromatographic study of stressed samples
1.4.1 Analytical HPLC

HPLC trails were taken to develop a stability indicating method for the separation and quantification of DLP and DPs using different buffers,pH conditions and different proportions of acetonitrile and methanol. Xterra RP18 column (250 mm×4.6 mm,3.5 μm) was used for separation. The optimized HPLC conditions were described in Table 3. The stressed samples were analyzed by HPLC method to monitor the formation of different DPs under various degradation conditions. DLP spiked with all impurities are shown in Fig. 1.

Table 3 LC conditions for analytical, preparative, LC-MS/MS and UPLC-MS/TOF analyses

Fig. 1 Chromatogram of DLP spiked with all impurities
1.4.2 Preparative HPLC

The stressed samples were targeted to preparative HPLC analysis with the objective to isolate oxidative DP (RRT 0.54 (DP Ⅰ)). The preparative method was developed by employing a mobile phase at basic pH on Inertsil ODS-3 column (250 mm×10 mm,5.0 μm). The optimized preparative LC conditions are described in Table 3. The impurity fractions were collected separately from several injections and pooled together after confirming the purities of each fraction. The solvent present in the pooled fraction was evaporated by using rotavapour under high vacuum. The aqueous solutions were lyophilized to solidify the impurities.

1.5 MS study of isolated DPs

MS/TOF and MS/MS studies were performed in ESI positive mode. The instrument parameters were first optimized to get the molecular ion peak of the DP. The same were subsequently modified to get complete fragmentation profile of purified DP. In a further step,the information on the origin of each individual fragment was obtained from MS2 studies.

1.5.1 LC-MS/MS

The ESI mass spectrum of the impurity was recorded on AB SCIEX 4000 QTRAP LC-MS/MS system. The samples were introduced into the system at the ion spray voltage of 5 500 V and the temperature was maintained at 400 ℃. GS1 and GS2 were optimized to 30 psi (206.85 kPa) and 35 psi (241.325 kPa) respectively and the declustering potential was 70 V. A mixture of water and acetonitrile in the proportion of 20:80 (v/v) was used as diluent for sample preparation and mass concentration of sample was 0.02 mg/mL. Analysis was carried out on Xterra RP18 column (250 mm×4.6 mm,3.5 μm) column. Based on the optimized HPLC conditions an MS compatible HPLC method was developed. The optimized LC conditions are described in Table 3.

1.5.2 UPLC-MS/TOF

The analysis was acquired using the lock spray to ensure accuracy and reproducibility. High resolution (wavelength (W) mode,full width half maximum (FWHM) 10 500) positive polarity scan responses were collected from m/z 100 to 1 000 at a rate of 1.0 s/scan. The source block and desolvation temperatures were 90 ℃ and 180 ℃,respectively. The nebulizer and desolvation gas (nitrogen) flows were 20 L/h and 450 L/h,respectively. The instrument parameters were used as capillary 3 000 V,cone 25 V,extractor 2 V and microchannel plate (MCP) 2 700 V. The acquisitions were done in scan mode. MS/TOF studies were performed in ESI positive mode. A mixture of water and acetonitrile in the proportion of 20:80 (v/v) was used as diluent for sample preparation and the mass concentration of sample was 0.02 mg/mL. ACQUITY UPLCTM BEH shield,RP18 column (100 mm×2.1 mm,1.7 μm) was used for separation. Based on MS compatible HPLC method,a UPLC method was developed. The optimized LC conditions are described in Table 3.

1.6 NMR study

NMR experiments (1D and 2D) were performed in DMSO-d6 at 25 ℃ as solvent. 1H NMR measurements were carried out at 500 MHz,while 13C NMR experiments were performed at 125 MHz. Proton and carbon chemical shifts were reported on δ scale in ppm,relative to tetra methyl silane (TMS) (δ=0.00 ppm (10-6)) and DMSO (δ=39.50 ppm) as internal standards in 1H and 13C NMR spectra respectively. Standard pulse sequences provided by Varian were used for 1D and 2D NMR data.

2 Results and discussion
2.1 Forced degradation study

Forced degradation is degradation of a drug substance or a drug product under conditions more severe than the accelerated stability conditions. Degradation studies were performed on DLP drug substance with an objective to establish the DPs of the drug substances,structure elucidation and intrinsic stability of DLP. The stress factors used for forced degradation studies included acid,base,neutral hydrolysis,thermal degradation,photolysis and oxidation. Hence there is no specification in regulatory guidelines about the stress conditions of pH,temperature and specific oxidizing agents to be used. We put efforts to optimize the degradation conditions to evaluate the degradation behavior of DLP. In all stress studies,trails were taken from mild to extreme stress conditions i. e. higher temperature,higher concentrations of acid,base and peroxide and prolonged exposure times to optimize the degradation conditions to obtain reasonable degradation of DLP. The optimized stress conditions are listed in Table 2. All these stressed samples were subjected to HPLC analysis.

2.2 HPLC study of stressed samples

All the stressed samples were analyzed by aforementioned HPLC method. In newly developed stability indicating HPLC method all the DPs and DLP were well separated. HPLC analysis revealed that the drug was highly unstable under acid,base,oxidative and thermal conditions and formed known and unknown impurities. It was moderately stable under photolytic degradation (Fig. 2). This complete degradation study also inferred that a small change in the stress conditions like concentration of stressors and exposure times resulted in a different degradation profile including type of formation of DPs and their percentages. The comparisons of formation of known and unknown DPs under different stress conditions by HPLC study are shown in Table 4.

Fig. 2 Overlay chromatograms of forced degradation studies of DLP

Table 4 Comparisons of formation of degradants in stress study
2.3 Isolation of DPs by preparative HPLC

Isolation of impurities (DPⅠ) by preparative HPLC was a challenging job as the target impurities were highly labile. It is indeed a major task to stabilize the impurities during its isolation. Hence it was observed that DPⅠ is very unstable to acidic pH,simple and efficient preparative HPLC method was developed by employing a basic pH mobile phase using ammonia as pH modifier. Several trials were performed to optimize the purity,yield and throughput. Finally a simple gradient system was developed on an Inertsil ODS-3 column (250 mm×10 mm,5.0 μm) with good resolution and a run time of 60 min. The chromatographic purity of DPⅠ was 99.1 and this sample was used for spectroscopic structural studies. The structures of DPⅠ and DLP are shown in Fig. 3.

Fig. 3 Chemical structures of DLP and DPⅠ with numbering
2.4 Structure elucidation of DPⅠ

The ESI-MS spectra of DPⅠ show only positive ionization and the molecular ion is observed at m/z 322.1 (Fig 4). The compound didn’t form lithium adduct ion and negative ESI-MS spectrum shows no peaks,suggesting that the molecular ion obtained is positively charged [25],i. e.,m/z 322.1 due to M+. The positive HR-MS spectrum shows peak at m/z 322.115 4 (Fig. 4),corresponding to a possible molecular formula C16H15N3F3O. In comparison,DPⅠ contains one hydrogen more and one oxygen and one sulphur atoms less than DLP. This indicates the elimination of SO (sulphur monoxide) moiety from the parent DLP and suggests rearrangement of benzimidazole and pyridine moieties to form DPⅠ. The plausible degradation pathways for DPⅠ are shown in Fig. 5. The comparisons of MS/MS spectra of DLP and DPⅠ don’t show any common fragment ions.

Fig. 4 HR MS and MS/MS data of DLP and DPⅠ a. MS spectrum of DLP; b. MS/MS spectrum of DLP; c. MS spectrum of DPⅠ; d. MS/MS spectrum of DPⅠ.

Fig. 5 Plausible degradation pathways for DPⅠ

The comparisons of 1H NMR spectra of DPⅠ with DLP (Fig. 6) show the absence of one methylene moiety (in DLP 4.83 & 4.76 ppm,Ha,Hb) and addition of one methyl signal (at 2.66 ppm,Table 5). The absent methylene moiety was found to be the one attached to sulphur in DLP. The benzimidazole,pyridine and trifluoro ethoxy methylene protons were found to be intact in DPⅠ. The methyl signal at 2.24 ppm (corresponding to C18) showed nuclear overhauser effect spectroscopy (NOESY) correlations with the methylene protons at 5.31 ppm and methyl protons at 2.66 ppm. The NOESY (Fig. 7) and heteronuclear multiple bond correlation (HMBC) (Fig. 8) correlations confirm that the methyl is substituted at ortho position to the methyl at 2.24 ppm on pyridine moiety.

Fig. 6 NMR spectra of DLP and DPⅠ

Table 5 1H and 13C NMR assignments for DLP and DP Ⅰ

Fig. 7 NOESY spectrum of DPⅠ

Fig. 8 HMBC spectrum of DPⅠ

This confirms that the methylene moiety in DLP has changed to a methyl moiety in DPⅠ. Based on double bond equivalence and the positively charged properties,the nitrogen in pyridine moiety in DPⅠ directly connected to the benzimidazole moiety with positive charge.Based on the above spectral data,the structure of DPⅠ was characterized as 1-(1H-benzo[d]imidazol-2-yl)-2,3-dimethyl-4-(2,2,2-trifluoroethoxy) pyridin-1-ium.

3 Conclusions

The drug substance of dexlansoprazole was subjected to stress studies and evaluated for degradation products. The unknown oxidation degradation products were isolated by a simple preparative method and characterized by NMR,MS/MS and MS/TOF spectroscopic techniques. The most probable structure was proposed for impurities based on the spectral data. The entire study will benefit in developing stable drug substances and drug products,and in recommending storage conditions and shelf lives.

Acknowledgement We would like to thank the management of Dr. Reddy’s Laboratories Ltd. for supporting this work. Cooperation from colleagues of Research & Development Department and Analytical Research & Development Department of Dr. Reddy’s Laboratories Ltd. is acknowledged.

References
[1]Dexlansoprazole. (2014-12-17). http://www.drugs.com/cons/dexlansoprazole.html   
[2]International Conference on Harmonization. ICH Q3A (R2), Impurities in New Drug Substances. 2006: 1
[3]International Conference on Harmonization. ICH Q3B (R2), Impurities in New Drug Products, 2006: 1
[4]U. S. Food and Drug Administration. Drug Stability Guidelines. 1987
[5]World Health Organization. WHO Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. Technical Report Series, No. 953, 2009
[6]Bartos D, Görög S. Curr Pharm Anal, 2008, 4: 215  
[7]Olsen B A, Castle B C, Myers D P. TrAC-Trends Anal Chem, 2006, 25: 796  
[8]Ahuja S, Alsante K M. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals. San Diego: Elsevier Science, 2003
[9]Singh S. J Pharm Biomed Anal, 2012, 69: 148  
[10]U. S. Food and Drug Administration. FDA Approves Name Change for Heartburn Drug Kapidex. [2015-08-05]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm203096.htm   
[11]Hotha K K, Vijaya Bharathi D, Jagadeesh B, et al. Biomed Chromatogr, 2012, 26: 192  
[12]Cirilli R, Ferretti R, Gallinella B, et al. J Pharmaceut Biomed, 2009, 50(1): 9  
[13]Battu S, Pottabathini V. Int J Pharm Pharm Sci, 2014, 6(10): 359
[14]Ramulu K, Rao B M, Someswara Rao N. Rasayan J Chem, 2013, 6(4): 274
[15]Srinivas K S V, Mukkanti K, Buchi Reddy R, et al. E-J Chem, 2010, 7(3): 844  
[16]Li W, Chen S, Hao L H, et al. Chinese Pharmaceutical Journal, 2010, 45(6): 471
[17]Bhawana N, Abhishek M, Poonam K. Anal Chem Ind J, 2010, 9(1): 137
[18]Reddy G M, Mukkanti K, Kumar T L, et al. Synth Commun, 2008, 38(20): 3477  
[19]Pai N R, Suhas Patil S. J Chem Pharm Res, 2013, 5(7): 121
[20]Rao P V, Kumar M N, Kumar M R. Sci Pharm, 2013, 81(1): 183  
[21]Luo Y, Xu L, Xu M, et al. Asian J Pharm Sci, 2012, 7(2): 149
[22]Petkovska R, Cornett C, Dimitrovska A. J Liq Chromatogr Relat Technol, 2008, 31(14): 2159  
[23]IFPMA. Stability Testing of New Drug Substances and Products Q1A (R2). International Conference on Harmonisation, Geneva, 2003
[24]IFPMA. Photo Stability Testing of New Drug Substances and Products Q1B. International Conference on Harmonisation, Geneva, 1996
[25]Mohan A. J Pharm Biomed Anal, 2008, 47: 183